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Abstract 1 
We describe the structural and antigenic properties of a soluble form of 2 
hepatitis C virus E2 envelope protein ectodomain ending at residue 661 (E2661) 3 
which is obtained in large quantities in a baculovirus/insect cell system. The 4 
protein is secreted to the cellular medium by virus-infected cells. E2661 is 5 
glycosylated and possesses a high tendency to self-associate. In fact, analytical 6 
ultracentrifugation and size exclusion chromatography studies show that the 7 
purified protein is mainly composed of dimers, trimers and tetramers being the 8 
dimer the smallest species present in solution. The secondary structure was 9 
determined by deconvolution of the far-UV circular dichroism spectrum yielding 10 
8% -helix structure, 47% extended structure and 45% non-ordered structure. The 11 
near-UV CD spectrum is indicative of a folded structure. The fluorescence 12 
emission spectrum indicates that Trp residues occupy a relatively low 13 
hydrophobic environment. Finally, E2661 binds to a monoclonal conformation 14 
specific antibody and to antibodies present in human sera from HCV-positive 15 
patients. All these features suggest that the secreted protein possesses a native-like 16 
conformation. The use of this independent folding domain may contribute to shed 17 
light on the biology of HCV and could also be used as a vaccine in the prevention 18 
of HCV infection. 19 
 20 
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1. Introduction 1 
 Hepatitis C virus (HCV) is an enveloped, positive-stranded RNA virus that 2 
belongs to the Hepacivirus genus of the Flaviviridae family (Lindenbach and 3 
Rice, 2001). HCV is a major cause of chronic hepatitis, liver cirrhosis, and 4 
hepatocellular carcinoma worldwide (Major et al., 2001). There is no vaccine for 5 
HCV, and current antiviral therapy is based on the use of polyethylene glycol-6 
modified interferon in combination with ribavirin. However, this treatment is 7 
expensive, relatively toxic, and effective in only half of the treated patients (Feld 8 
and Hoofnagle, 2005).  9 
 HCV encodes two envelope glycoproteins, E1 and E2. They are classified 10 
as type I integral transmembrane proteins with an N-terminal ectodomain and a C-11 
terminal hydrophobic domain anchor. The ectodomains contain 5 or 6 and 11 N-12 
glycosylation sites, respectively. During their synthesis, the ectodomains of HCV 13 
envelope glycoproteins are targeted to the endoplasmic reticulum lumen, where 14 
they are highly modified by N-linked glycosylation (Goffard and Dubuisson, 15 
2003). In vitro expression studies have shown that both glycoproteins associate to 16 
form heterodimers, which accumulate in the endoplasmic reticulum, the proposed 17 
site for HCV assembly and budding (Op De Beeck et al., 2001).  18 
 The E2 glycoprotein extends from amino acid 384 to 746 of the 19 
polyprotein from which it derives. The transmembrane domain has been shown to 20 
encompass residues 718-746 (Cocquerel et al., 1998) and it has been demonstrated 21 
that only polypeptide chains ending before or at residue 661 are properly folded 22 
(Michalak et al., 1997). The E2 glycoprotein carries regions of extreme 23 
hypervariability (HVR1 and HVR2) (Hijikata et al., 1991; Kato et al., 1992). The 24 
most variable region, HVR-1, is located within the N-terminal 27 residues (384-25 
 4
411) of E2, while HVR-2 resides in the 476-480 fragment. E2 protein has been 1 
described to interact with the large extracellular loop of human CD81, its putative 2 
cellular receptor (Flint et al., 1999; Owsianka et al., 2001; Pileri et al., 1998). It 3 
also elicits production of neutralizing antibodies against the virus, and is involved 4 
in viral morphogenesis (Bartosch and Cosset, 2006; Bartosch et al., 2005). The E2 5 
protein is considered as a major candidate for anti-HCV vaccine. Antibodies 6 
specific for epitopes within HVR-1 have been reported to inhibit binding of E2 to 7 
cells and to block HCV infectivity in vitro and in vivo (Habersetzer et al., 1998; 8 
Shimizu et al., 1996; Zibert et al., 1999). Despite this, relatively little is known 9 
about this protein. 10 
 Because of the difficulties in propagating HCV in cell culture, many 11 
aspects of HCV life cycle remain unclear. A major advance in the investigation of 12 
HCV entry was the development of pseudoparticles (HCVpp), consisting of native 13 
HCV envelope glycoproteins E1 and E2 assembled into retroviral core particles 14 
(Bartosch et al., 2003; Hsu et al., 2003). This system is potentially powerful to 15 
identify and characterize molecules that block HCV entry. Furthermore, data 16 
obtained with HCVpp can also now be confirmed with the help of the recently 17 
developed cell culture system that allows efficient amplification of HCV (Wakita 18 
et al., 2005; Zhong et al., 2005). 19 
 Previous reports suggest that E1 and E2 interact to form a complex, which 20 
has been proposed as a functional subunit of HCV virions (Dubuisson et al., 1994; 21 
Ralston et al., 1993). Purified HCV glycoprotein complexes expressed by using 22 
vaccinia virus are non-covalently associated. However, in heterologous expression 23 
systems, E1 and E2 have a high tendency to form heterogeneous disulfide-linked 24 
aggregates, which could represent misfolded complexes (Cocquerel et al., 2003). 25 
Knowledge of the three-dimensional structure of HCV envelope protein E2 will 26 
 5
be of great value in the quest for a vaccine, in explaining existing data and in 1 
designing novel experiments. Current understanding of HCV envelope proteins is 2 
based on mammalian cell culture transient expression assays with viral and non-3 
viral vectors. These systems produce very low levels of heterogeneous protein due 4 
to glycosylation and aggregation, and it is difficult to distinguish between 5 
molecules that undergo productive and non-productive folding (Flint et al., 2000). 6 
In the absence of high levels of native E2, some other complexes, such as E1E2 7 
glycoproteins reconstituted into liposomes (Lambot et al., 2002) or virus-like 8 
particles expressed in insect cell systems (Clayton et al., 2002; Wellnitz et al., 9 
2002), have been used to study virus–cell interactions. In this paper, we describe 10 
the cloning, expression and purification of the ectodomain of E2 in a 11 
baculovirus/insect cell system, as well as the characterization of its structural and 12 
antigenic properties. It behaves as an independent folding domain with native-like 13 
properties. Several criteria indicate that it is correctly folded and processed. The 14 
protein is secreted to the cell supernatant, it is glycosylated and contains 15 
carbohydrates bound at least through N-glycosidic bonds. Furthermore, it self-16 
associates into dimeric and higher order soluble forms which are recognized by a 17 
conformation specific antibody and by antibodies present in sera from HCV-18 
positive patients. The structural properties of the recombinant protein derived 19 
from circular dichroism and fluorescence spectroscopic studies are described. 20 
21 
 6
2. Materials and methods 1 
 2 
2.1. Construction of recombinant transfer vector 3 
DNA encoding the ectodomain of E2 protein, residues 384-661 (E2661), 4 
was inserted into a baculovirus transfer vector pAcGP67A (Pharmingen) with the 5 
addition of a six-histidine tag (His tag) immediately 3´ of the multiple cloning 6 
site. The cDNA encoding E2661 was obtained by RT-PCR from the viral RNA of a 7 
strain 1HCV-PT, genotype 1a, using the following primers: 8 
5´- cgc gga tcc c cat cac cat cac cat cac GAA ACC CAC GTC ACC GGG – 3´ 9 
(forward) 10 
5´- ggg gaa ttc a CTC GGA CCT GTC CCT GTC – 3´ (reverse) 11 
 Two restriction sites, BamHI and EcoRI, were created at the 5´ and 3´ ends 12 
of E2661 gene, respectively. The amplified reaction product was subcloned into 13 
pCR2.1 plasmid (Invitrogen) digested with BamHI and EcoRI. The resulting 14 
plasmid was digested with these restriction enzymes and, finally, the E2661 cDNA 15 
was cloned into the pAcGP67A baculovirus transfer vector downstream of the 16 
strong polh promoter to create pAcGP67A-E2661.  17 
 18 
2.2. Insect cell culture and transfections 19 
 The insect cell line Spodoptera frugiperda (Sf9) was cultured in Insect X-20 
Press serum-free media (BioWhittaker) at 27 ºC. Sf9 cells were cotransfected with 21 
BaculogoldTM DNA (Pharmingen) and the recombinant transfer vector 22 
pAcGP67A-E2661 as indicated by the manufacturer. Several rounds of culture 23 
amplified the recombinant virus, and a high titer virus stock solution was 24 
harvested. To express the protein on a larger scale, High FiveTM insect cells 25 
 7
(Invitrogen) were grown in Insect X-Press serum-free media prior to infection 1 
with high titer virus (>108 pfu/ml) at a multiplicity of infection of 5-10. 2 
 3 
2.3. Purification of E2661 4 
 Typically, 500 ml of recombinant baculovirus-infected insect cell cultures 5 
were harvested approximately 120 h postinfection and the cells pelleted by 6 
centrifugation at 5000 g for 10 min. The supernatant was dialyzed against 50 mM 7 
Tris-HCl, pH 8.0, 0.3 M NaCl and loaded onto a Ni2+-Nitrilotriacetic acid agarose 8 
(Ni-NTA agarose) column (Qiagen) equilibrated with the same buffer. It was then 9 
washed with dialysis buffer containing 10 mM imidazole and later 30 mM 10 
imidazole. The recombinant E2661 protein was eluted with 200 mM imidazole in 11 
dialysis buffer. The presence of E2661 was monitored by SDS-PAGE throughout 12 
the purification. 13 
 14 
2.4. Protein analysis 15 
 Protein concentrations were determined spectrophotometrically from the 16 
absorbance at 280 nm and the extinction coefficient calculated from the amino 17 
acid analysis. The absorption spectra were recorded on a Beckman DU-640 18 
spectrophotometer. The amino acid analysis of hydrolyzed aliquots was 19 
performed on a Beckman 6300 automatic analyzer. Automated Edman protein 20 
degradation of E2661 was performed using an Applied gas-phase sequencer (model 21 
494). 22 
 23 
2.5. Protein Deglycosylation 24 
 Protein samples were digested with N-glycosidase F (PNGase F, Roche) 25 
for 16 h at 37 ºC in 20 mM sodium phosphate, pH 7.0, 50 mM EDTA, and 1% 26 
 8
(p/v) octylglucoside. Ole e 1 protein was used as a control of deglycosylation (van 1 
Ree et al., 2000). Digested samples were mixed with 3X Laemmli sample buffer 2 
and analyzed by SDS-PAGE. The proteins were stained with Coomassie brilliant 3 
blue R 250 and also transferred to nitrocellulose membranes that were 4 
subsequently incubated with the lectin concanavalin A conjugated to biotin 5 
(Pierce). The glycoproteins were detected using HRP-streptavidin at a 1:1000 6 
dilution. 7 
 8 
2.6. Mass spectrometry analysis 9 
 The molecular mass of E2661 was determined by Matrix-Assisted Laser 10 
Desorption/Ionization-Time-of-Flight (MALDI-TOF) mass spectroscopy (MS) 11 
using a MALDI-TOF Bruker REFLEX IV (Bruker-Francen Analytic GmbH, 12 
Bremen, Germany) equipped with reflectron analyzer, delayed extraction 13 
capabilities and AutoXecute software for automated spectra acquisition. The 14 
matrix was a saturated solution of sinapinic acid (Sigma).  15 
 In order to identify E2661, the protein was digested with trypsin. The 16 
resulting peptides were analyzed by MALDI-TOF MS and Surface-Enhanced 17 
Laser Desorption/Ionization-Time-of-Flight (SELDI-TOF) MS using a SELDI-18 
TOF PBS-II mass spectrometer (Ciphergen ProteinChip System). For protein 19 
identification, tryptic peptide masses were transferred to BioTools 2.0 interface 20 
(Bruker Daltonics) to search in the NCBInr database using Mascot software 21 
(www.matrixscience.com; Matrix Science, London, UK). 22 
 23 
2.7. Circular Dichroism 24 
 CD measurements were carried out on a Jasco spectropolarimeter, model 25 
J-715. All the measurements were carried out at 25 ºC with cells thermostated 26 
 9
with a Neslab RTE-111 water bath. Far-UV CD and near-UV CD spectra were 1 
measured at a protein concentration of 0.15 mg/ml and 0.5 mg/ml respectively, 2 
using protein dialyzed against 30 mM MOPS, pH 7.0, 0.1 M NaCl. The 3 
pathlengths were 1 and 5 mm, respectively. The contribution of the buffer was 4 
always subtracted. The spectra were calculated by using 110 as the mean residue 5 
molecular mass and the results are expressed in terms of residue molar ellipticity 6 
in degcm2dmol-1. The secondary structure of the protein was evaluated by 7 
computer fit of the dichroism spectra according to Convex Constraint Analysis 8 
(CCA) (Perczel et al., 1991). This method relies on an algorithm that calculates 9 
the contribution of the secondary structure elements that give rise to the original 10 
spectral curve without referring to spectra from model systems. The secondary 11 
structure was also predicted by the GOR IV method (Garnier et al., 1996).  12 
 13 
2.8. Fluorescence spectroscopy 14 
 Emission spectra were obtained at 25 ºC using an SLM AMINCO 8000C 15 
spectrofluorimeter. Excitation and emission slit widths were set at 4 nm. The 16 
protein concentration was 0.05 mg/ml and a 0.4 x 1 cm cuvette was used. Buffer 17 
was 30 mM MOPS, pH 7.0, 100 mM NaCl. Excitation was performed at 275 or 18 
295 nm, and the emission spectra were recorded over the range 285-450 nm. The 19 
contribution of the buffer was always subtracted. The tyrosine contribution to the 20 
emission spectra was calculated by subtracting the emission spectrum measured at 21 
exc = 295 nm multiplied by a factor from that measured at exc = 275 nm. The 22 
factor was obtained from the ratio between the fluorescence intensities measured 23 
with exc = 275 and exc = 295 nm at wavelengths above 380 nm, where there is no 24 
tyrosine contribution. 25 
 10
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2.9. Fluorescence quenching 1 
 In order to determine the average accessibility of Trp residues, 2 
fluorescence quenching experiments with acrylamide and KI were performed at 3 
25 ºC. Protein fluorescence was quenched by the presence of increasing amounts 4 
of acrylamide (0-600 mM) or KI (0-1M). The KI stock solution also contained 5 
0.18 M sodium thiosulfate in order to prevent the formation of 3I . The 6 
fluorescence measurements were determined as continuous emission spectra 7 
between 300 and 450 nm with excitation at 290 nm. The emission spectra were 8 
corrected for dilution. The protein concentration was 0.1 mg/ml. Fluorescence 9 
intensities at the emission maximum were used for calculations. The fluorescence 10 
quenching data were analyzed according to the Stern-Volmer equation: 11 
F0/F = 1 + KSV [Q] 12 
where F0 and F are the fluorescence intensities in the absence and presence of 13 
quenchers, respectively, KSV is the collisional Stern-Volmer constant, and [Q] is 14 
the quencher concentration. When the plot was not linear, the fluorescence 15 
quenching data were analyzed according to the modified Stern-Volmer equation:  16 
 17 
 18 
where fa is the fraction of fluorescence accessible to the quenching agent (Lehrer, 19 
1971). 20 
 21 
2.10. SDS-PAGE 22 
 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 23 
was performed according to Laemmli using 15% polyacrylamide gels (Laemmli, 24 
1970). Samples were subjected to gel electrophoresis under either nonreducing or 25 
 11
reducing conditions (with 5% (v/v) -mercaptoethanol) and the proteins were 1 
stained with Coomassie brilliant blue R-250. The molecular mass of the protein 2 
bands was estimated by comparison with protein markers of known molecular 3 
mass (Prestained SDS-PAGE Standards, Bio-Rad). 4 
 5 
2.11. Western blotting 6 
After SDS-PAGE, proteins were transferred to nitrocellulose membranes 7 
(Hybond-ECL; Amersham) in 48 mM Tris/HCl, pH 9.0, containing 39 mM 8 
glycine, 0.0375% SDS and 20% (v/v) methanol, for 1 h at 1 mA/cm2, by using a 9 
V20-SDB apparatus (Scie-Plas). To detect E2661, membranes were incubated with 10 
a HRP-conjugated monoclonal anti-His (Sigma) at a 1:3000 dilution. The 11 
peroxidase reaction was developed with 3, 3’-diaminobenzidine 12 
tetrahydrochloride/H2O2. When the membranes were incubated with individual 13 
sera from HCV-positive human patients, E2661 was detected via Enhanced 14 
Chemiluminiscence (ECL). After blotting, the membrane was incubated with the 15 
human sera diluted to 1:20, washed and incubated with HRP-conjugated anti-16 
human IgG (Fc) (Sigma) diluted at 1:1000. E2661 was detected by incubating the 17 
membranes with ECL reagents (Amersham Life Sciences) and exposure to 18 
photographic film. 19 
 20 
2.12. Analytical ultracentrifugation 21 
 The sedimentation velocity experiments were carried out on a Beckman 22 
Optima XL-A analytical ultracentrifuge equipped with UV-VIS optics detection 23 
system, using an An60Ti rotor and 12 mm double-sector centerpieces. The 24 
experiments were performed at 20 ºC with a protein concentration of 5 M. The 25 
buffer employed was 50 mM Tris-HCl, 300 mM NaCl, pH 7.0. The sedimentation 26 
 12
coefficient distributions were calculated by modelling of the sedimentation 1 
velocity data using the c(s) method (Schuck, 2000), as implemented in the 2 
SEDFIT program, from which the corresponding sedimentation coefficients (s-3 
values) were obtained. 4 
 5 
2.13. Size Exclusion Chromatography 6 
The purified E2661 was chromatographed on a FPLC (Pharmacia) system 7 
by using a Superdex G-200 column equilibrated with 50 mM Tris-HCl, 300 mM 8 
NaCl, pH 8.0. The separation was monitored at 280 nm. The elution volume of 9 
each peak was compared with that of molecular mass markers. 10 
 11 
2.14. Enzyme Linked Immunosorbent Assay (ELISA) 12 
96 wells microtitre plates (Costar 3690) were coated overnight at 4 ºC with 13 
100 ng/well of purified recombinant E2661 diluted to 1 g/ml in 0.05 M carbonate-14 
bicarbonate buffer, pH 9.6. Unbound antigen was discarded, and the wells were 15 
blocked with 3% non-fat dry milk in PBS for 60 min at room temperature. After 16 
washing, the wells were incubated at 37ºC for 2 h with human serum. Eight HCV-17 
positive human sera and ten HCV-negative human sera were used at a dilution of 18 
1:200. The plates were washed three times with PBS/0.05% Tween 20 and 19 
incubated at 37ºC for 1 h with HRP-conjugated anti-human IgG (Fc) diluted at 20 
1:10.000. Bound antibodies were detected by adding 100 mM sodium citrate, pH 21 
5.0, 4% Methanol buffer containing H2O2 and the substrate o-phenylenediamine 22 
dihydrochloride (Merck). The optical density at 492 nm was measured using an 23 
ELISA Expert 96 microplate reader (ASYS Hitech). Sera from infected and 24 
control patients were provided by Dr. Fernando Vivanco (Fundación Jiménez 25 
Díaz, Madrid, Spain). 26 
 13
2.15. Immunoprecipitation 1 
 A 50 l aliquot of rabbit anti-mouse immunoglobulin G bound to Sepharose 2 
beads (Pharmacia-LKB) was incubated with 2 l of anti-E2 monoclonal antibody 3 
H53 or 2 l of rabbit serum for 1 h at 4 ºC in 10 mM Tris-Cl, pH 7.5, containing 4 
0.2% NP-40, 150 mM NaCl and 2 mM EDTA (TBS-NP-40). The MAb H53 is 5 
conformation-dependent and was a generous gift of Dr. Jean Dubuisson. Beads were 6 
then incubated with 2 g of purified E2661 for1 h at 4ºC. Between each step, the 7 
beads were washed twice with TBS–NP-40. After the last step, they were washed 8 
three times with this buffer and once with distilled water. The precipitates were then 9 
boiled for 5 min in SDS-PAGE sample buffer and analyzed on a 12% 10 
polyacrylamide gel. After electrophoresis and transfer to nitrocellulose membranes, 11 
protein E2661 was detected by incubating the membranes with a polyclonal goat anti-12 
E2 antibody (USBiological) at a 1:500 dilution followed with a rabbit anti-goat 13 
antibody conjugated to HRP diluted at 1:3000. The peroxidase reaction was 14 
developed with 3,3’-diaminobenzidine tetrahydrochloride/H2O2. 15 
16 
 14
3. Results and Discussion 1 
 2 
Previous attempts have been made to obtain either full length E2 or E2 3 
ectodomain. Expression of E2661 in Escherichia coli led to the production of 4 
inclusion bodies which were solubilized with chaotropic agents. The non-5 
glycosylated recombinant protein thus obtained was able to interact with the virus 6 
receptor CD81 and it was recognized by a number of anti-E2 antibodies (Hüssy et 7 
al., 1997; Xiang et al., 2006; Yurkova et al., 2004). The fact that E2661 produced 8 
in E. coli is insoluble, points to glycosylation as an indispensable factor for the 9 
global folding of E2. In fact, it has been reported that the glycans of HCV 10 
envelope glycoproteins play a major role in protein folding and/or in HCV entry 11 
(Dubuisson and Rice, 1996; Goffard et al., 2005; Helenius and Aebi, 2001). The 12 
glycosylation also modulates the neutralizing activity of anti-HCV antibodies. At 13 
least three glycans in positions N1, N6 and N11 of E2 reduce the sensitivity of 14 
HCV pseudoparticles to antibody neutralization (Helle et al., 2007). In contrast, 15 
the glycosylation does not seem to be necessary for the binding to its receptor 16 
CD81 (Xiang et al., 2006; Yurkova et al., 2004). 17 
 The HCV structural E2 protein has also been produced in mammalian 18 
expression systems (Owsianka et al., 2001; Patel et al., 2000) and yeast cells 19 
(Martinez-Donato et al., 2006). In all cases, the majority of the secreted E2661 20 
exhibited a molecular mass much higher than that expected because of the 21 
hyperglycosylation of the protein. Moreover, the levels of expression are so low 22 
that the recombinant proteins can only be used to detect HCV-specific antibodies 23 
in human sera. The expression of different polypeptide forms of E2 in 24 
recombinant baculovirus-infected insect or human hepatoma cells has also been 25 
 15
reported although no structural information is given (Cerino et al., 1997; Hsu et 1 
al., 1993; Hüssy et al., 1997; Hüssy et al., 1996; Matsuo et al., 2006; Matsuura et 2 
al., 1992). Thus, by using different recombinant constructs containing the E2 3 
protein terminating at residue 662, several E2 related proteins were observed (Hsu 4 
et al., 1993). These were partially purified by cutting the protein bands from 5 
preparative SDS-PAGE and electroeluting them in PAGE running buffer. Their 6 
immunoreactivity was tested using sera from patients chronically infected with 7 
HCV and only 10% reacted with the E2 protein (Hsu et al., 1993). On the other 8 
hand, a protein comprising residues 406-660 of E2 was secreted by Sf9 cells 9 
infected with recombinant baculovirus. The protein was purified under native 10 
conditions and used to show that it was glycosylated and that it reacted with 11 
antibodies from HCV-seropositive patients (Hüssy et al., 1996). Finally, a 12 
truncated soluble E2 protein, spanning residues 390-683, expressed in insect cells 13 
using a baculovirus vector was purified under native conditions from the culture 14 
supernatant. It was used to study the human antibody response to HCV infection 15 
(Cerino et al., 1997). 16 
We describe herein the expression and purification of large quantities of a 17 
soluble form of E2 ectodomain (E2661) which has allowed us to determine its 18 
structural and antigenic properties. To overcome the hyperglycosilation problems 19 
encountered in yeast, we have expressed E2661 protein using a baculovirus 20 
expression system. 21 
 22 
3.1. Expression and purification of E2661 from High FiveTM cells 23 
 To produce the recombinant virus that expresses the E2661 protein with a 24 
6x His tag, the gene was first cloned into the pAcGP67A transfer vector that uses 25 
the gp67 secretory sequence of the baculovirus envelope protein. Next, the 26 
 16
recombinant vector was transfected along with wild-type viral DNA into Sf9 cells 1 
and in a homologous recombination event, the E2661 gene was inserted into the 2 
viral genome. The protein was expressed by infecting a new batch of insect cells 3 
using amplified recombinant virus. Cells were grown and protocols were carried 4 
out as described in Materials and methods. 5 
Recombinant E2661 would have 287 amino acids, 278 corresponding to 6 
positions 384 to 661 of E2 and 9 extra amino acids at the N-terminal end, the 7 
sequence ADP due to cloning plus the 6xHis. After 48 h post-infection, virus-8 
infected cells produced several proteins which were recognized by an anti-His 9 
antibody, a major one with a molecular mass of 50 kDa and other minors that 10 
could correspond to less glycosylated products and/or polypeptide chains 11 
truncated at their C-terminal (data not shown). Of all these proteins, a single one 12 
with a molecular mass of about 48 kDa was partially (60%) secreted to the cell 13 
supernatant. 14 
When High FiveTM cells were infected, this protein was almost completely 15 
secreted to the extracellular medium. The accumulated amount of secreted protein 16 
was monitored directly at various post-infection times by Western blot analysis 17 
(data not shown). The highest amount was obtained 5 days post-infection. From 18 
day 5, the amount decreased because insect cell lysosomal proteases were released 19 
from lysed cells.  20 
 The protein secreted to the extracellular medium was purified by a Ni-21 
NTA-agarose column as described in Materials and methods. The fractions eluted 22 
with 200 mM imidazole contained a protein which behaves as a single band in 23 
SDS-PAGE with a molecular mass of 48.3 kDa (Fig. 1, lane 1). Its purity was 24 
assessed to be higher than 95% in the presence of reducing agents (Fig. 1, lane 1). 25 
The yield of the process was 5-6 mg of protein per liter of media. The molecular 26 
 17
mass of the purified protein is similar to that provided by other authors when 1 
E2661 is obtained by transient expression in mammalian cells (Flint et al., 2000).  2 
 3 
3.2. Biochemical characterization of E2661 4 
Several studies indicated that the secreted protein was indeed E2661. When 5 
analyzed by UV spectroscopy, purified E2661 gave an absorption spectrum 6 
characteristic of a soluble protein. It exhibited a maximum at 278 nm and a 7 
shoulder at 290 nm (data not shown). A value of 2.73 for E0.1% at 280 nm was 8 
experimentally calculated. This specified extinction coefficient together with the 9 
absorbance at 280 nm were used to determine the protein concentration in all 10 
subsequent experiments. The amino acid composition of the recombinant protein 11 
was determined by amino acid analysis, being almost identical to that predicted 12 
from the DNA sequence. On the other hand, the Edman degradation of purified 13 
E2661 confirmed that the amino-terminal sequence was ADPH, indicating that the 14 
gp67 signal sequence had been cleaved. Finally, the identity of E2661 was checked 15 
by mass spectrometry after trypsin hydrolysis. The analysis of the tryptic peptides 16 
was carried out by MALDI-TOF and SELDI-TOF. In both cases, experimentally 17 
measured peptide masses were compared with the theoretical ones derived from 18 
the E2661 sequence, using FindMond software package from Expasy Proteomics 19 
Server (www.expasy.org). This analysis assigned measured masses to peptides 20 
which cover almost 70% of the entire sequence (Table 1). However, some of the 21 
Asn residues in the putatively identified peptides are predicted to be N-22 
glycosylation sites (Goffard and Dubuisson, 2003), specifically those which 23 
correspond to positions 44, 50, 57, 74, 202, 249 and 272, and the carbohydrate 24 
moiety would modify their masses. Hence, assigned masses correspond to either 25 
peptides which are not glycosylated or to other regions of the protein. In any case, 26 
 18
it seems clear that the isolated protein really corresponds to the ectodomain of E2. 1 
On the other hand, the fact that the peptides containing the Cys residues 55, 223, 2 
233, 246, 270 and 278 are observed in the non-reduced sample, would indicate 3 
that at least 6 out of the 17 cysteines of E2 ectodomain are not forming inter or 4 
intramolecular disulphide bridges. 5 
SDS-PAGE in the presence of reducing agents showed a single band at 6 
48.3 kDa that could correspond to the monomer (Fig. 1, lane 1). However, in the 7 
absence of reducing agents four main bands were observed (Fig. 1, lane 2). These 8 
have molecular masses that could correspond to monomeric, dimeric, trimeric and 9 
tetrameric forms of E2661. Also, higher order structures which do not enter the gel 10 
were observed. Therefore, E2661 would tend to self-associate through hydrophobic 11 
interactions and/or disulfide bridges. Mass spectrometry analysis of the intact 12 
protein confirmed the oligomeric nature of E2661. MALDI-TOF yielded four peaks 13 
with molecular masses of 43.4, 81.1, 121.1 and 160.8 kDa (data not shown), 14 
which could also correspond to the same species observed by SDS-PAGE. The 15 
lower mass of the dimer, trimer and tetramer, as expected from that of the 16 
monomer, 43.4 kDa, could be due to the fact that the spectrometer is calibrated at 17 
the mass of the monomer and the error for the massess of the high order structures 18 
is considerable higher. On the other hand, the difference between the molecular 19 
mass values obtained by MS and electrophoresis could be due to the presence of 20 
the 6x His tag which promotes a lower migration on SDS-PAGE.  21 
The oligomeric nature of E2661 was also assessed by analytical 22 
ultracentrifugation. Sedimentation equilibrium experiments showed that the 23 
soluble protein was present as a mixture of molecular species. The polydispersity 24 
of the protein prompted us to use sedimentation velocity to determine the nature 25 
of the main species present in solution. Using this method, the presence of several 26 
 19
oligomeric species of E2661 was detected (Fig. 2). The calculated molecular mass 1 
of the most abundant species was 9612 kDa with a sedimentation coefficient of 2 
4.3 Ѕ. Considering that the molecular mass of the E2661 monomer determined by 3 
SDS-PAGE is 48.3 kDa, the major form found by analytical ultracentrifugation is 4 
compatible with a dimer. The area under the peaks allowed us to estimate that the 5 
dimer accounts for 30-40% of the total species present. The sedimentation 6 
coefficients of the other molecular forms observed are compatible with tetramers 7 
(20%), hexamers (15%) and higher forms (25%). A similar behaviour was 8 
observed when the purified protein was chromatographed on a Superdex G-200 9 
FPLC column. Moreover, when the peak which eluted at the dimer volume was 10 
subjected to SDS-PAGE in the absence of reducing agents, only a band with the 11 
molecular mass of the monomer was observed (data not shown). 12 
Therefore, as indicated by sedimentation velocity and size exclusion 13 
chromatography experiments, E2661 has a high tendency to self-assocciate, being 14 
the dimer the smallest form present. The presence of dimers had also been 15 
proposed previously by other workers (Yagnik et al., 2000). The observed dimer 16 
is maintained by hydrophobic interactions which are disrupted by SDS when the 17 
protein is analyzed in SDS-PAGE in the absence of reducing agents. The dimeric 18 
forms which are observed by SDS-PAGE in the absence of reducing agents 19 
should come from the higher order oligomers which are disrupted by SDS, being 20 
the disulfide bridges somehow involved in the formation of some of the 21 
oligomeric species detected. However, it should be pointed out that the oligomers 22 
must be different from mere aggregates of misfolded forms of the protein since 23 
the spectroscopic properties of the dimer isolated from a Superdex G-200 column 24 
are practically indistinguishable from those of the E2661 purified from the cellular 25 
medium and the far-UV CD spectrum is maintained in the presence of the 26 
 20
reducing agent tris-(2-carboxyethyl)-phosphine (data not shown). Thus, as 1 
previously proposed, the high tendency to form oligomers must be just an intrinsic 2 
property of E2 sequence (Dubuisson, 2000). 3 
 On the other hand, as mentioned above, E2 is predicted to contain several 4 
glycosylation sites (Goffard and Dubuisson, 2003). A global sequence analysis 5 
indicates that it has 11 potential glycosylation sites, most of which are well-6 
conserved (Goffard and Dubuisson, 2003; Helle et al., 2007; Zhang et al., 2004a; 7 
Zhang et al., 2004b). The purified E2661 behaves in SDS-PAGE in the presence of 8 
reducing agents as a single band with a molecular mass of 48.3 kDa while the 9 
theoretical mass based on the amino acid sequence is 31.65 kDa. Therefore, E2661 10 
must be glycosylated. In fact, E2661 is recognized by concanavalin A (Fig. 3B, 11 
lane 1). Moreover, the enzymatic deglycosylation with PNGase, which removes 12 
carbohydrates bound through N-glycosydic bonds, rendered a double band at 35-13 
37 kDa (Fig. 3A, lane 2) which must correspond to partially deglycosylated forms 14 
since both bands were recognized by concanavalin A (Fig. 3B, lane 2). Thus, 15 
E2661 must contain some N-glycosidic bonds which are not accessible to the 16 
PNGase although the existence of O-glycosidic bonds can not be precluded. As a 17 
control of deglycosylation the allergen Ole e1 was used (van Ree et al., 2000). 18 
The results obtained indicated that deglycosylation was working properly (Fig. 19 
3A, lanes 3-4).  20 
 21 
3.3. Spectroscopic analysis of E2661  22 
 The spectroscopic characterization of E2661 was carried out by means of 23 
circular dichroism and fluorescence spectroscopy. Far-UV CD spectrum of E2661 24 
showed a minimum at 207 (Fig. 4A), indicative of a high percentage of non-25 
regular structure. This spectrum is maintained in the presence of a 1 mM 26 
 21
concentration of the reducing agent tris-(2-carboxyethyl)-phosphine. 1 
Deconvolution of this spectrum using the program Convex Constraint Analysis 2 
(CCA) (Perczel et al., 1991) yielded the percentages of secondary structure given 3 
in Table 2. The predictive GOR IV method (Garnier et al., 1996), which is based 4 
upon the propensity of each amino acid to adopt a particular secondary structure, 5 
also indicates that helical structures are almost absent and that the main ordered 6 
structures are -sheets (Table 2). The near-UV CD spectrum of E2661 has two 7 
minima at 268 and 300 nm whose ellipticity values were –37 and –30 8 
degreecm2dmol-1, respectively (Fig. 4B). These two dichroic bands reveal the 9 
asymmetric nature of the microenvironment of Trp and Tyr residues and, hence, 10 
the folded character of the purified protein. 11 
 The fluorescence emission spectrum of E2661 showed a maximum at 334 12 
nm (Fig. 5), which is typical of Trp residues in relatively low hydrophobic 13 
environments. The shape of the spectrum indicates that Tyr fluorescence is 14 
quenched by near residues or by energy transfer to Trp residues. The difference 15 
between the fluorescence spectra obtained upon excitation at 275 and 295 nm 16 
provides the low contribution of Tyr residues to the protein fluorescence (Fig. 5).  17 
 Acrylamide and iodide quenching of protein fluorescence were used to 18 
gain information on the degree of exposure of the fluorophores. As dynamic 19 
quenchers, both agents exert their action through collision with the fluorophores 20 
(Lehrer, 1971). Stern-Volmer plot of acrylamide quenching of E2661 fluorescence 21 
was linear indicating that there is only one population of Trp residues accessible 22 
to the quencher (data not shown). Moreover, the value of fa = 0.98 indicates that 23 
all fluorophores were accessible to acrylamide. 24 
 Since iodide is charged and highly hydrated, it will only interact 25 
with those fluorophores at or near the surface. Stern-Volmer plot of quenching of 26 
 22
E2661 fluorescence by iodide was linear up to 0.4 M, with a marked upward 1 
curvature above this concentration (data not shown). At iodide concentrations 2 
higher than 0.4 M the maximum of the emission spectrum undergoes a red shift 3 
which indicates that the protein is denatured, with two populations of Trp 4 
residues, accessible and non-accessible to iodide. Moreover, the population of 5 
fluorophores accessible to quencher is homogeneous, since when quenching of 6 
E2661 fluorescence data were plotted according to the modified Stern-Volmer 7 
relationship, a linear plot was observed (Fig. 6). The value of fa = 0.83 calculated 8 
from this plot indicates that eight of the ten Trp residues were accessible to 9 
iodide. The low value of KSV, 5.2 M-1, indicated that the accessible Trp residues 10 
are not at the surface since KSV would otherwise be higher (KSV for free N-acetyl-11 
L-tryptophanamide in aqueous solution is 17.5 M-1) (Lehrer, 1971). Taken 12 
together, all these results indicate that E2661 recombinant protein has a somehow 13 
open conformation, but different from a denatured state. 14 
 15 
3.4. Antigenic properties of E2661 16 
 A panel of eight HCV-positive human sera and ten HCV-negative human 17 
sera was used to assess the antigenic properties of the E2661 recombinant protein. 18 
All sera were tested by ELISA for E2-specific antibodies as described in Material 19 
and methods. E2661 recombinant protein was able to bind to antibodies present in 20 
all HCV-positive human sera at a dilution of 1:200. The optical density values 21 
reached with the positive sera (Fig. 7, sera 1-8) were much higher than those of 22 
the negative controls (Fig. 7, sera 9 and 10; only two of the ten negative sera are 23 
depicted). The observed differences in the value of the optical density at 492 nm 24 
are consistent with the HCV titer as determined by COBAS TaqMan HCV test 25 
(Hu et al., 2005) (data not shown). 26 
 23
 The structural properties of the different epitopes were assessed by 1 
Western blot analysis. The effect of the denaturation with SDS and -2 
mercaptoethanol on the reactivity of E2 against the human sera was tested. As 3 
depicted in Fig. 7, sera 1, 2, 3, 4 and 8 reacted to a different extent with denatured 4 
and reduced E2661 while sera 5, 6 and 7 gave almost no reaction (Fig. 7). This 5 
suggests that some of the antibodies present in HCV-positive human sera bind to 6 
conformation-dependent epitopes. Therefore, E2661 should contain both 7 
continuous and discontinuous antigenic determinants. Reduction would destroy 8 
the antigenic reactivity of discontinuous epitopes thus indicating the role of 9 
disulfide bridges in stabilizing their conformation.  10 
 Finally, the conformation of E2661 was examined by immunoprecipitation 11 
with an anti-E2 conformation-dependent monoclonal antibody, H53. The E2661 12 
protein was efficiently immunoprecipitated by the antibody, suggesting that the 13 
purified protein possesses a native-like conformation. Moreover, all the 14 
oligomeric forms were able to react with the antibody. 15 
 16 
HCV envelope glycoproteins, E1 and E2, have been shown to form 17 
noncovalent heterodimers as well as heterogeneous disulfide-linked aggregates 18 
(Dubuisson et al., 1994; Ralston et al., 1993). Characterization of the noncovalent 19 
heterodimer with conformation dependent monoclonal antibodies has suggested 20 
that this oligomer is likely the prebudding form of the functional complex 21 
(Deleersnyder et al., 1997).  Michalak and coworkers (1997) have shown that the 22 
folding of E1 is helped by the coexpression of E2 (Michalak et al., 1997). 23 
Moreover, two earlier studies indicate that HCV envelope glycoproteins cooperate 24 
for the formation of a functional complex and that both glycoproteins have to be 25 
co-expressed to analyze their functional properties (Brazzoli et al., 2005; 26 
 24
Cocquerel et al., 2003). Taking into account the results described in this paper it 1 
seems reasonable to asume that E2661 recombinant protein is folded in a native 2 
conformation and presents antigenic properties similar to E2 assembled in the 3 
HCV virion. Therefore, E2 ectodomain would not need the presence of E1 to 4 
achieve its native structure, it represents the structural core of functional E2, and it 5 
behaves as an independent folding domain. Now that high levels of properly 6 
folded E2661 can be obtained, further studies of its three-dimensional structure as 7 
well as its role in receptor binding and in the fusion mechanism of the HCV can 8 
be carried out. Also, and since E2661 containing different sequences of the HVR1 9 
can be obtained (M. Rodríguez-Rodríguez and F. Gavilanes, unpublished data), a 10 
mixture of polypeptide chains corresponding to the ectodomain of E2 envelope 11 
protein could be used as a vaccine in the prevention of HCV infection. 12 
13 
 25
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Figure captions 1 
 2 
Fig. 1. Oligomeric nature of E2661. The purified E2661 was subjected to SDS-3 
PAGE in the presence (lane 1) and in the absence (lane 2) of reducing agent. (P) 4 
Protein size markers. (a) monomer, (b) dimer, (c) trimer and (d) tetramer. The gel 5 
was stained with Coomassie Brilliant blue R-250. 6 
 7 
Fig. 2. Sedimentation velocity analysis of E2661. The results are shown as the 8 
sedimentation coefficient distribution c(s). The experiment was carried out at 5 9 
M native E2661. 10 
 11 
Fig. 3. Analysis of the deglycosylation of E2661 by PNGase. (A) SDS-PAGE 12 
stained with Coomassie blue. (1) E2661 untreated; (2) E2661 treated with PNGase; 13 
(3 and 4) Ole e 1 protein used as control before and after treatment with PNGase, 14 
respectively (van Ree et al., 2000); (P) Protein size markers. (B) SDS-PAGE 15 
stained with concanavalin A. (1) E2661 untreated; (2) E2661 treated with PNGase. 16 
After transferring, the nitrocellulose membranes were incubated with biotinylated 17 
concanavalin A and the proteins were detected using peroxidase-conjugated 18 
streptavidin as described in the Materials and methods section. The digestion with 19 
PNGase was carried out for 16 h at 37 ºC in 20 mM sodium phosphate, pH 7.0, 50 20 
mM EDTA, and 1% (v/v) octylglucoside. 21 
 22 
Fig. 4. Circular dichroism spectra of E2661. (A) Far-UV CD spectrum of E2661 23 
at pH 7.0. The spectrum was recorded between 190 and 250 nm with a protein 24 
concentration of 0.15 mg/ml in a cylindrical cuvette of 0.1 cm pathlength. (B) 25 
 35
Near-UV CD spectrum of E2661 at pH 7.0. The pathlength of the cuvette was 0.5 1 
cm and the protein concentration was 0.5 mg/ml. The buffer was MOPS 30 mM, 2 
pH 7.0, 100 mM NaCl. Both spectra were recorded five times, averaged and 3 
corrected for buffer contributions. Data were collected at 25 ºC and are expressed 4 
as residue molar ellipticity. 5 
 6 
Fig. 5. Fluorescence emission spectra of E2661. The excitation wavelength was 7 
275 nm () and 295 nm (---). The emission spectra were recorded between 300 8 
and 450 nm. The spectrum obtained after excitation at 295 nm was normalized at 9 
wavelengths above 380 nm. The contribution of Tyr residues () to the emission 10 
spectrum was calculated as described in the Materials and Methods section. 11 
Protein concentration was 0.05 mg/ml. The buffer was sodium phosphate 20 mM, 12 
pH 7.5, 100 mM NaCl. Spectra were collected at 25 ºC. The contribution of the 13 
buffer was always subtracted. 14 
 15 
Fig. 6.  Modified Stern-Volmer plot of iodide quenching of E2661 fluorescence. 16 
The values of the fluorescence at 334 nm (F) were obtained from the emission 17 
spectra of E2661 in the presence of increasing amounts of iodide (0-1 M). The 18 
emission spectra were recorded with an excitation of 290 nm. The protein 19 
concentration was 0.1 mg/ml. The value of F0 was measured for the same E2661 20 
sample in the absence of iodide. The data were plotted according to the modified 21 
Stern-Volmer relationship as described in the Materials and Methods section and 22 
the parameters were deduced by linear regression. 23 
 24 
Fig. 7. Reactivity of E2661 against HCV-positive and negative human sera. The 25 
upper part shows the results obtained in an ELISA assay as described in the 26 
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Materials and Methods section. Eight HCV-positive human sera (1-8) and ten HCV-1 
negative human sera were used at a dilution of 1:200. Only the results obtained with 2 
two negative controls (9 and 10) are shown since all of them gave virtually the same 3 
optical density. Bound antibodies were detected with peroxidase conjugated anti-4 
human IgG (Fc) diluted at 1:10000. The lower part shows the results of the Western 5 
blot analysis after electrophoresis in the presence of SDS and -mercaptoethanol. 6 
The nitrocellulose membranes which were incubated with individual sera from HCV-7 
positive and negative patients at a dilution of 1:20, were developed with peroxidase-8 
conjugate goat anti-human IgG diluted at 1:1000 and E2661 was detected with ECL 9 
detection reagents. 10 
11 
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Tables 1 
Table 1  2 
 3 
Tryptic peptides of native E2661 recombinant protein identified by SELDI-4 
TOF and MALDI-TOF MS.  5 
 6 
aThe molecular mass corresponds to the experimental value. bThe cysteine residues are 7 
shown in bold. cThe numbers indicate the position of the aminoacid in the cloned protein. 8 
9 
 SELDI-TOF  
Molecular Massa Peptideb Positionc 
750.110 CNLEDR 278-283 
961.520 HPEATYSR 215-222 
1021.260 CNLEDRDR 278-285 
1028.580 CLVNYPYR 233-240 
1048.550 MYVGGVEHR 257-265 
1064.540 LEAACNWTR 266-274 
1074.560 CGSGPWITPR 223-232 
1089.850 KHPEATYSR 214-222 
1800.030 LWHYPCTINYTIFK 241-254 
2092.400 MYVGGVEHRLEAACNWTR 257-274 
2184.610 SVCGPVYCFTPSPVVVGTTDR 127-147 
2531.800 VCGAPPCVIGGVGNNTLHCPTDCFR 189-213 
2659.660 VCGAPPCVIGGVGNNTLHCPTDCFRK 189-214 
2809.090 CLVNYPYRLWHYPCTINYTIFK 233-254 
3474.510 ADPHHHHHHETHVTGGTAAQTTAGLVSLLSPG
AK 
1-34 
4347.460 QDIQLINTNGSWHINSTALNCNDSLYTGWLAGL
FYHHK 
35-72 
 MALDI-TOF  
996.420 FNSSGCPER 73-81 
1028.580 CLVNYPYR 233-240 
1048.550 MYVGGVEHR 257-265 
1064.540 LEAACNWTR 266-274 
1074.560 CGSGPWITPR 223-232 
2092.400 MYVGGVEHRLEAACNWTR 257-274 
2184.610 SVCGPVYCFTPSPVVVGTTDR 127-147 
2531.800 VCGAPPCVIGGVGNNTLHCPTDCFR 189-213 
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Table 2 1 
Secondary structure of E2661.  2 
 3 
 4 
 5 
 6 
aThe experimental values  were calculated from the far-UV CD spectrum by using the 7 
deconvolution program CCA (Perczel et al., 1991). bThe theoretical values were calculated 8 
by GOR IV method (Garnier et al., 1996). 9 
 10 
   % Experimentala Theoreticalb 
-helix 8 2 
 -sheet 47 34 
Non-ordered 45 64 
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